1Witt O, Deubzer HE, Milde T, et al. HDAC family: What are the cancer relevant targets[J]. Cancer letters 2009, 277(1):8-21.
2Bolden JE, Peart MJ, Johnstone RW: Anticancer activities [J]. Nature reviews of histone deaeetylase inhibitors Drug discovery 2006, 5(9) :769-784.
3Bojang P, Jr., Ramos KS: The promise and failures of epigenetic therapies for cancer treatment [J]. Cancer treatment reviews 2014, 40 (1):153 -169.
4Fraga MF, Ballestar E, Villar- Garea A, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer[J]. Nature genetics 2005, 37(4):391 -400.
5Ozdag H, Teschendorff AE, Ahmed AA, et al: Differential expression of selected histone modifier genes in human solid cancers [J]. BMC genomics 2006, 7:90.
6Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer, a tissue microarray analysis [J]. Breast cancer research and treatment 2005, 90 (1):15-23.
7Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo[J]. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14(6):1669-1677.
8West AC, Johnstone RW: New and emerging HDAC inhibitors for cancer treatment [J]. The Journal of clinical investigation 2014, 124 (1) : 30 -39.
9Johnstone RW: Histone - deacetylase inhibitors: novel drugs for the treatment of cancer [J]. Nature reviews Drug discovery 2002, 1(4):287 -299.
10Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer[J]. Nature reviews Cancer 2006, 6(1):38-51.
